	US 12,268,777 B2
	Compositions and methods for treating eosinophilic disorders
Seema S. Aceves, Solana Beach, CA (US); Ranjan Dohil, San Diego, CA (US); and Quan Nhu, San Diego, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Jan. 4, 2023, as Appl. No. 18/150,152.
Application 18/150,152 is a division of application No. 16/894,784, filed on Jun. 6, 2020, granted, now 11,547,664.
Claims priority of provisional application 62/858,951, filed on Jun. 7, 2019.
Prior Publication US 2023/0218518 A1, Jul. 13, 2023
Int. Cl. A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/426 (2006.01); A61K 31/573 (2006.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01)

CPC A61K 9/0095 (2013.01) [A61K 9/20 (2013.01); A61K 9/4808 (2013.01); A61K 31/426 (2013.01); A61K 31/573 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01)]

11 Claims

1. A method of preventing or alleviating esophageal inflammation and fibrosis in a subject comprising orally administering to the subject a pharmaceutical composition comprising a corticosteroid and one or more thiazolidinediones (TZD(s)) in an oral syrup formulation.